Liposarcoma metastatic

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Kinase inhibitor 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 1 Phase II: 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Universitaet Muenster Academic
    TTF-NGR
    2024-516392-33-00 1 country 2021 n=126
    Recruiting

Phase II

1 trial
  • Region Skane Academic
    PEMIGATINIB; RETIFANLIMAB
    2022-501993-21-00 3 countries 2024 n=33 Orphan
    Recruiting

Phase I (First in Human)

1 trial
  • Pfizer Inc. Commercial
    PF-07220060 MONOHYDRATE
    2024-512120-11-00 2 countries 2022 n=62
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 1 Phase I (First in Human) 0
Region Skane Academic 1 Phase II 1
Universitaet Muenster Academic 1 Phase III 1
New trials by year
2021
1
2022
1
2024
1
← All indication landscapes